Modulating immune pathways in SCLC cells

In C04, M. Hölzel will seek to enhance chemokine expression by SCLC cells, in order to promote T cell recruitment and efficacy of immune checkpoint inhibition (ICI). The H3K9 histone dimethyltransferases EHMT1/2 were identified as drug targets to enforce interferon-stimulated gene and chemokine expression. M. Hölzel will thus analyze the molecular mechanisms of EHMT1/2 function and the implications of their inhibition. Furthermore, combinations of EHMT1/2 inhibitors with ICI will be explored in vivo expecting improved therapeutic efficacy through enhanced T cell recruitment. Clinical relevance of the findings will be assessed with the aim of identifying genomic and non-genomic correlates of EHTM1/2 inhibitor efficacy. By working with B04, C04 will search for additional other epigenetic modifiers that control interferon-stimulated gene and chemokine expression in SCLC.

Principal Investigator

Univ. Prof. Dr. med. Michael Hölzel SFB1399
Univ. Prof. Dr. med. Michael Hölzel

Professor (W3)

University Hospital Bonn

Institute of Experimental Oncology

Curriculum Vitae (CV)